Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposomes versus FOLFIRI plus bevacizumab in second-line metastatic colorectal cancer
ChiCTR2400088240Phase 2Not yet recruiting
- Sponsor
- The First People's Hospital of Kunshan
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan in metastatic colon cancer (mCRC) (2 arms), sponsored by The First People's Hospital of Kunshan. Primary endpoint: Objective response rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
irinotecan
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on ChiCTR2400088240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088240.